
Vives Louvain Technology Fund
Description
Vives Louvain Technology Fund is a multi-sector technology fund based in Louvain-la-Neuve, Belgium, with a strong strategic partnership with UCLouvain. The fund's primary mission is to valorize research and foster the growth of innovative deep tech companies, often originating as spin-offs from UCLouvain and other Belgian universities, alongside other promising early-stage ventures. Vives plays a crucial role in bridging academic research with commercial application, providing essential capital and strategic support to nascent technologies.
The fund has successfully raised significant capital across multiple iterations, demonstrating its enduring commitment to the Belgian tech ecosystem. Collectively, Vives I (launched in 2010), Vives II (2016), and Vives III (2022) have amassed over €100 million in capital. The most recent fund, Vives III, specifically commands a capital of €40 million, underscoring its capacity for new investments and continued support for its portfolio.
Vives focuses on seed and early-stage investments, targeting companies across a diverse range of technology sectors including biotech, medtech, deeptech, engineering, IT, and cleantech. Their typical initial investment in a first round ranges from €200,000 to €2 million, with a clear strategy for providing follow-on funding to support portfolio companies through subsequent growth stages. To date, Vives has invested in more than 30 companies, actively contributing to the development and scaling of high-potential ventures within Belgium and beyond. The fund prides itself on offering not just capital, but also active guidance, leveraging its extensive network and expertise to help entrepreneurs navigate the challenges of commercialization and market expansion.
Investor Profile
Vives Louvain Technology Fund has backed more than 25 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 4% of its total and boasts 3 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series A, Series Unknown rounds (top funding stages).
- Majority of deals are located in Belgium, France, United States.
- Strong thematic focus on Health Care, Biotechnology, Wellness.
- Typical check size: $200K – $2M.
Stage Focus
- Series B (36%)
- Series A (36%)
- Series Unknown (12%)
- Seed (12%)
- Series C (4%)
Country Focus
- Belgium (76%)
- France (12%)
- United States (8%)
Industry Focus
- Health Care
- Biotechnology
- Wellness
- Agtech
- Dietary Supplements
- Nutraceutical
- Electronics
- Medical
- Therapeutics
- Health Diagnostics
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.